Weed and Fatty Liver: Risks and UK Guidance

Weed and fatty liver disease is a topic of growing interest as cannabis use becomes more widespread across the UK. Fatty liver disease, particularly metabolic dysfunction-associated steatotic liver disease (MASLD), affects around one in three UK adults and is closely linked to obesity, insulin resistance, and lifestyle factors. Understanding how cannabis use may interact with liver health is important for anyone managing this condition. This article explores the current evidence on cannabis and liver disease, the specific risks for those with established liver conditions, and the lifestyle changes most likely to make a meaningful difference.

What is fatty liver disease and how does it develop?

Fatty liver disease occurs when excess fat accumulates in liver cells, most commonly due to obesity, insulin resistance, type 2 diabetes, or alcohol use. Early-stage disease is generally reversible with lifestyle changes, but persistent inflammation can progress to fibrosis or cirrhosis.

Fatty liver disease occurs when excess fat accumulates within liver cells, impairing the organ's ability to function normally. There are two main types: alcohol-related fatty liver disease (ARLD), caused by heavy or prolonged alcohol consumption, and metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD). MASLD is the terminology adopted in the 2023 international nomenclature consensus (EASL/EASD/EASO) and is increasingly used by UK clinical bodies; NHS and BSG guidance continues to reference both terms during the transition period.^[1]

MASLD develops when the liver struggles to process and export fat efficiently, often in the context of obesity, type 2 diabetes, high blood pressure, or elevated blood lipids. These conditions are closely linked to insulin resistance, which disrupts normal fat metabolism and encourages fat storage within liver tissue. The condition is common in the UK, with NHS estimates suggesting it affects around one in three adults to some degree, though many people have no symptoms in the early stages.^[2] When persistent inflammation accompanies the fat accumulation, the condition is termed metabolic dysfunction-associated steatohepatitis (MASH), which carries a higher risk of progression.

Without intervention, fatty liver disease can progress through a spectrum of severity. In some individuals, persistent inflammation leads to liver scarring (fibrosis), which may advance to cirrhosis or, in rare cases, liver cancer. Early-stage fatty liver is generally reversible with appropriate lifestyle changes, making timely identification important.

In primary care, initial assessment typically involves blood tests including a FIB-4 score (calculated from age, liver enzymes, and platelet count), which helps stratify fibrosis risk.^[25][26] Age-adjusted FIB-4 thresholds are used to guide onward investigation. Where intermediate or elevated risk is identified, an enhanced liver fibrosis (ELF) test or transient elastography (FibroScan) may be arranged.^[3][5] It is worth noting that standard ultrasound can miss mild steatosis, so a normal ultrasound does not exclude MASLD. Referral to a hepatology specialist is guided by these results, in line with NICE NG49 and BSG MASLD guidance. A GP can advise on which assessments are appropriate for an individual's circumstances.

Can smoking weed make fatty liver disease worse?

Smoking cannabis may worsen fatty liver disease by stimulating appetite, promoting weight gain, and potentially activating CB1 receptors that encourage fat accumulation in the liver. Direct causation in humans has not been firmly established, but people with MASLD should discuss cannabis use with their GP.

There is currently no definitive clinical evidence that smoking cannabis directly causes fatty liver disease, but several mechanisms suggest it may contribute to worsening the condition in people who already have it. Cannabis contains cannabinoids, primarily tetrahydrocannabinol (THC) and cannabidiol (CBD), which interact with the body's endocannabinoid system. This system plays a role in regulating metabolism, appetite, and fat storage, including within the liver.

THC, the psychoactive component of cannabis, is known to stimulate appetite, a phenomenon commonly referred to as the "munchies." Regular cannabis use may therefore contribute to increased caloric intake, weight gain, and worsening insulin resistance, all of which are established drivers of MASLD progression. These links are biologically plausible and consistent with observational data on cannabis use and metabolic outcomes, though human evidence directly linking THC-induced appetite changes to liver disease progression remains limited.

Preclinical (animal and cell-based) studies have explored the role of cannabinoid CB1 receptors in promoting fat accumulation and fibrosis within the liver. Activation of CB1 receptors has been associated with increased lipogenesis (fat production) in liver cells in these laboratory studies, raising the possibility that regular THC exposure could have a pro-fibrotic effect.^[6] It is important to note that direct causation in humans has not been firmly established from this preclinical evidence.

Smoking cannabis also introduces combustion products into the body, which carry cardiovascular and inflammatory risks broadly similar to those associated with tobacco smoke, though the liver-specific effects of inhaled cannabis smoke are less well characterised. People with existing fatty liver disease should discuss cannabis use openly with their GP, who can provide personalised guidance.

What does the current research say about cannabis and liver health?

Research on cannabis and liver health is mixed, with some studies linking heavy use to greater hepatic steatosis and others finding no significant harm in moderate users. No robust human trials support CBD as a treatment for liver disease, and no UK body has approved cannabis-derived products for MASLD.

The research on cannabis and liver health is mixed, and no firm clinical consensus has been reached. Some observational studies have suggested that daily or heavy cannabis use is associated with a higher prevalence of hepatic steatosis (fat in the liver), particularly in people who are overweight or have other metabolic risk factors. Conversely, a number of studies have found that moderate cannabis use is not independently associated with significant liver damage in otherwise healthy individuals. Systematic reviews of the available human data reflect this uncertainty and highlight the methodological limitations of existing studies.

One area of particular interest is the potential anti-inflammatory and antifibrotic properties of CBD. Some preclinical research has suggested that CBD may reduce liver inflammation and slow fibrosis progression in animal models, but these findings have not been replicated in robust human clinical trials. It would therefore be premature to consider CBD a treatment for liver disease. No UK regulatory body, including NICE or the MHRA, has approved any cannabis-derived product specifically for fatty liver disease. NICE NG144 sets out the regulatory framework for cannabis-based medicinal products (CBPMs) in the UK; licensed CBPMs exist for specific indications such as certain epilepsies and chemotherapy-induced nausea, but none are indicated for MASLD or liver disease.^[7][8]

The Food Standards Agency (FSA) has issued consumer safety advice on CBD products, including guidance on daily intake limits and a caution that CBD may affect liver enzymes.^[10][11] People with liver disease considering CBD supplements should be aware of this and discuss use with their GP or specialist before starting.

A complicating factor in interpreting the research is that cannabis users often have other lifestyle factors, such as alcohol use, tobacco smoking, or poor diet, that independently affect liver health. Separating the specific contribution of cannabis from these confounders is methodologically challenging. Furthermore, the potency and composition of cannabis products vary considerably, making it difficult to draw generalisable conclusions across studies. The overall picture suggests that heavy, regular cannabis use is unlikely to be beneficial for liver health, and may be harmful in those with pre-existing liver conditions, but more high-quality human research is needed before definitive guidance can be issued.

Are there any risks of using cannabis if you already have liver disease?

People with established liver disease face heightened risks from cannabis, including impaired cannabinoid metabolism, worsening of hepatic encephalopathy, and potential drug interactions via cytochrome P450 pathways. Those with cirrhosis or advanced fibrosis should be particularly cautious about psychoactive or sedating substances.

People with established liver disease face specific risks from cannabis use that go beyond those seen in the general population. The liver is responsible for metabolising many substances, including cannabinoids. In individuals with significant liver impairment, such as those with cirrhosis or advanced fibrosis, the liver's reduced metabolic capacity can lead to altered processing of THC and other cannabinoids, potentially resulting in unpredictable or prolonged effects.

In advanced liver disease, psychoactive or sedating substances, including THC, may contribute to or worsen hepatic encephalopathy, a serious complication in which impaired liver function affects brain function. People with cirrhosis or advanced fibrosis should be particularly cautious about any substance with sedating or psychoactive properties.

There is also a concern around cannabis hyperemesis syndrome (CHS), a condition characterised by recurrent, severe nausea and vomiting in heavy cannabis users. Repeated vomiting can lead to dehydration and electrolyte disturbances, which place additional strain on an already compromised liver.

For people taking prescribed medications for liver disease or related conditions, cannabis may interact with drug metabolism pathways, particularly those involving cytochrome P450 enzymes in the liver.^[11][12] This could potentially affect the efficacy or safety of prescribed treatments. Anyone using cannabis or CBD products alongside prescribed medication should inform their GP or specialist before doing so, as adjustments to treatment may be necessary.

If you experience sudden worsening of symptoms, seek prompt medical attention. Urgent symptoms include jaundice (yellowing of the skin or eyes), severe abdominal pain, vomiting blood or passing black tarry stools, marked swelling of the abdomen or legs, high fever with abdominal pain, or new confusion or drowsiness. Contact your GP promptly for concerning but non-emergency symptoms. For severe or rapidly worsening symptoms, attend A&E or call 999.

Healthcare professionals and patients can report suspected adverse effects of medicines, herbal products, and complementary products, including prescribed cannabis-based products used medicinally, to the MHRA via the Yellow Card scheme (yellowcard.mhra.gov.uk).

What lifestyle changes can help improve a fatty liver?

Sustained lifestyle changes, including a 5 to 10 per cent reduction in body weight, a Mediterranean-style diet, and at least 150 minutes of moderate physical activity per week, are the most evidence-based approaches to improving fatty liver disease. Reducing alcohol and reviewing cannabis use with a GP are also strongly advisable.

Sustained lifestyle modification is the most effective and evidence-based approach to improving fatty liver disease, particularly in the early and moderate stages. NICE NG49 and BSG MASLD guidance indicate that even a modest reduction in body weight, typically around 5 to 10 per cent of total body weight, can lead to meaningful reductions in liver fat and inflammation.^[3][4] Weight loss achieved through a combination of dietary change and increased physical activity is preferred over rapid or extreme dieting, which can paradoxically worsen liver health.

Dietary recommendations for fatty liver disease focus on reducing intake of ultra-processed foods, refined carbohydrates, added sugars, and saturated fats, while increasing consumption of vegetables, wholegrains, lean proteins, and healthy fats such as those found in oily fish and olive oil. The Mediterranean dietary pattern has a reasonable evidence base for improving liver health markers and is broadly consistent with NHS dietary guidance.^[18]

Regular physical activity is independently beneficial for liver health, even in the absence of significant weight loss. Both aerobic exercise (such as brisk walking, cycling, or swimming) and resistance training have been shown to reduce liver fat.^[19][20] The UK Chief Medical Officers' Physical Activity Guidelines recommend at least 150 minutes of moderate-intensity activity per week for adults.^[15][16]

Reducing or eliminating alcohol is essential, as even moderate alcohol intake can accelerate liver damage in people with MASLD. In those with steatohepatitis or cirrhosis, specialist guidance generally advises abstinence. The UK Chief Medical Officers' low-risk drinking guidelines recommend no more than 14 units per week for adults who choose to drink, spread over three or more days, with additional caution for those with liver disease. Reviewing cannabis use with a GP is also advisable, given the potential metabolic and hepatic effects discussed above.

NHS Tier 2 and Tier 3 weight management services and the NHS Digital Weight Management Programme may offer structured support; availability varies by Integrated Care Board (ICB) area, so a GP can advise on local options. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, which may be relevant for those seeking structured support alongside GP care. Smoking cessation, blood pressure management, and optimising blood glucose and cholesterol levels are additional priorities that a GP or specialist can help coordinate.

Scientific References

1. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease.
2. Non-alcoholic fatty liver disease (NAFLD).
3. Metabolic dysfunction-associated steatotic liver disease (MASLD): assessment and management (NG49).
4. Metabolic dysfunction-associated steatotic liver disease (MASLD): assessment and management – full guideline PDF (NG49).
5. Metabolic dysfunction-associated steatotic liver disease (MASLD): recommendations for research (NG49).
6. Inhibiting CB1 receptors improves lipogenesis in an in vitro model of fatty liver.
7. Cannabis-based medicinal products (NG144) – overview.
8. Cannabis-based medicinal products (NG144) – recommendations.
9. Medical cannabis (cannabis oil).
10. Joint position paper from ACNFP and COT: provisional acceptable daily intake for cannabidiol (CBD).
11. The Influence of CBD and THC on Hepatic Enzymes.
12. Effects of simulated exogenous and endogenous lipid microenvironments on cannabidiol disposition and cytochrome P450 2C19-mediated drug interactions. Drug Metabolism and Disposition..
13. An Overview of Cannabinoid Interactions With Common Pediatric Antineoplastic Agents. Pediatric Blood & Cancer..
14. Literature review on forensic implications of illicit drug metabolism: A medicinal chemistry perspective. Journal of Forensic and Legal Medicine..
15. UK Chief Medical Officers' physical activity guidelines.
16. Physical activity guidelines for adults aged 19 to 64.
17. Alcohol consumption: advice on low risk drinking – UK Chief Medical Officers' guidelines.
18. The impact of dietary interventions on liver health biomarkers in individuals with MASLD: a systematic literature review and meta-analysis of RCTs. European Journal of Nutrition..
19. Resistance training for metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis. Frontiers in Physiology..
20. Metabolic benefits of changing sedentary lifestyles in nonalcoholic fatty liver disease: a meta-analysis of RCTs. Therapeutic Advances in Endocrinology and Metabolism..
21. Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: a meta-analysis. Metabolism: Clinical and Experimental..
22. Noninvasive Detection of Clinically Significant Fibrosis in Biopsy-Proven MASLD. Medicina (Kaunas)..
23. Strategy to Improve Diagnostic Performance of Hepatic Steatosis Grading Using Ultrasound. Medicina (Kaunas)..
24. Metabolic-dysfunction associated steatotic liver disease: clinical features and noninvasive methods of detection in young adults with obesity. European Journal of Gastroenterology & Hepatology..
25. Liver Disease, Liver Fibrosis, and the Invasive-Management Gap in Acute Myocardial Infarction: FIB-4 Stratification. Journal of Cardiovascular Development and Disease..
26. A Cross-Sectional Observational Study of NAFLD Assessed by Fibrosis Index in Patients With Type 2 Diabetes Mellitus. Cureus..
27. Performance of Serum-Based Non-Invasive Fibrosis Scores Compared with Liver Biopsy in Patients with Chronic Hepatitis B. Medicina (Kaunas)..

Frequently Asked Questions